RARE · Ultragenyx Pharmaceutical Inc.
$26.49
+0.11 (+0.42%)
At close · Aug 14
Market Cap
$2.61B
Shares
98.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$26.49
Open$26.30
Day$25.75–26.58
52W close$18.50–36.54
Avg vol 30d2.0M
Short int15.0M · 15.2% float · 8.3d
Short vol40%
Last earningsAug 4, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
−5%
below
RSI (14)
46
neutral
MACD trend
Positive
52-week position
44%
mid-range
Momentum
relative strength
1-month return
−10%
trailing
6-month return
+18%
trailing
YTD return
+15%
this year
Relative strength
+4%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $28 › 200d $27 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +61 funds added
Insider flow
Distributing
Net -$50.1K over 90 days · 100% sells
Short interest
Rising
15.18% of float · ▲ +11.4% MoM · 8.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
309 holders — mid 3-yr range
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
EPS growth
+7%
Y/Y
Free cash flow
$-472.0M
Balance sheet
$421.0M
net cash
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
full year 2026
Total revenue
$730M – $760M
Crysvita revenue
$500M – $520M
Dojolvi revenue
$100M – $110M
Combined R&D and SG&A operating expenses
-3% – 0%
full year 2027
Combined R&D and SG&A operating expenses
at least -15%
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Total revenue
· this year
$640M – $670M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
−5%
Bearish
RSI (14)
46
Neutral
MACD trend
Positive
Bullish
52-week position
44%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $28 › 200d $27 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +61 funds added
Insider flow
Distributing
Net -$50.1K over 90 days · 100% sells
Short interest
Rising
15.18% of float · ▲ +11.4% MoM · 8.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
309 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $19
Now $26 · 44%
Range high $37
vs 200-day avg -1%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Charges related to the termination of UX143 manufacturing agreements and other related activitie | $40M | the first half of 2026 | — |
| Employee severance payments and other employee-related costs | $10M | the first half of 2026 | — |
| Total restructuring and restructuring-related charges | $50M | the first half of 2026 | — |
| Workforce reduction | 10% | the first half of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RARE
this stock
Ultragenyx Pharmaceutical Inc.
|
$2.61B | +15.2% | +20.2% | — | 15.2% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RARE | +2.2% | -9.5% | +17.7% | +6.3% | +15.2% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +1.8% | -14.0% | +3.9% | +2.4% | +1.3% |
Key facts
CIK
1515673
CUSIP
90400D108
13F (30d)
327 filings
293 filers
Visit website
Investor relations